Medicenna Therapeutics CorpOTCQX International:MDNAFView on Canadian Exchange
- LAST PRICE1.1290
- TODAY'S CHANGE (%)0.0720 (6.8117%)
- Bid / Lots1.1200/ 30
- Ask / Lots1.2200/ 1
- Open / Previous Close1.0900 / 1.0570
- Day Range
- 52 Week Range
- Volume105,756
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDNAF |
|---|---|---|
| 09:32 ET | 3880 | 1.06 |
| 09:46 ET | 1400 | 1.073 |
| 10:06 ET | 3200 | 1.0755 |
| 10:08 ET | 2500 | 1.07 |
| 10:09 ET | 1800 | 1.07 |
| 10:13 ET | 1000 | 1.07 |
| 10:38 ET | 1000 | 1.067 |
| 10:45 ET | 13000 | 1.0675 |
| 10:58 ET | 500 | 1.0655 |
| 11:09 ET | 175 | 1.065 |
| 11:12 ET | 10500 | 1.08 |
| 11:14 ET | 475 | 1.07 |
| 11:18 ET | 1200 | 1.0795 |
| 11:54 ET | 1243 | 1.086 |
| 11:56 ET | 500 | 1.082 |
| 11:59 ET | 2175 | 1.085 |
| 12:28 ET | 500 | 1.0895 |
| 12:33 ET | 3300 | 1.1 |
| 12:55 ET | 800 | 1.09 |
| 12:57 ET | 500 | 1.08 |
| 01:38 ET | 10000 | 1.0925 |
| 02:34 ET | 3000 | 1.0975 |
| 02:36 ET | 1800 | 1.1 |
| 02:39 ET | 400 | 1.1 |
| 02:43 ET | 2500 | 1.107 |
| 03:26 ET | 500 | 1.127 |
| 03:44 ET | 25000 | 1.1275 |
| 03:46 ET | 1221 | 1.125 |
| 03:50 ET | 1000 | 1.1235 |
| 03:53 ET | 1000 | 1.1255 |
| 04:00 ET | 1750 | 1.129 |
Nov 15, 2024
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update, from 7:30AM ET on Friday Nov 15, 2024 by Dow Jones
7:30AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
Nov 11, 2024
Nov 8, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medicenna Therapeutics Corp | 120.0M | --- | --- |
Company Information
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Contact Information
- Headquarters
- 2 Bloor St W., 7Th FloorTORONTO, ON, Canada M4W 3E2
- Phone
- 416-648-5555
- Fax
- 416-648-5555
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $120.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 76.4M |
Medicenna Therapeutics Corp does not pay a dividend. | |
Beta | 1.04 |
EPS | $-0.37 |
Book Value | $0.07 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
